Abstract
Although intracerebral tumors were the first type to be investigated clinically with positron emission tomography (PET) using the most important clinical tracer, [18F]-fluorodeoxyglucose (FDG), the implementation into clinical practice has been long surpassed by the use of whole-body PET scanning in general oncology [1]. This embracing of whole-body PET scanning has meant a general technical upgrade in many hospitals, creating the opportunity to study many other indications as well. For brain tumors, the focus here will thus be on the use of FDG and amino acid/amino acid analogue tracers, as these are predicted to play the largest clinical roles in the years to come.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Di Chiro G, DeLaPaz RL, Brooks RA et al (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxy — glucose and positron emission tomography Neurology 32:1323–1329
Varrone A, Asenbaum S, Vander Borght T et al (2009) EANM procedure guidelines for PET brain imaging using [(18)F]FDG, version 2. Eur J Nucl Med Mol Imaging 36:2103–2110
Spence AM, Muzi M, Mankoff DA et al (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter J Nucl Med 45:1653–1659
Fulham MJ, Brunetti A, Aloj L et al (1995) Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids J. Neurosurg. 83:657–664
Ishizu K, Sadato N, Yonekura Y et al (1994) Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 18:12–15
Bergstrom M, Collins VP, Ehrin E et al (1983) Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr 7:1062–1066
Popperl G, Kreth FW, Herms J et al (2006) Analysis of 18FFET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47:393–403
Kaim AH, Weber B, Kurrer MO et al (2002) (18)F-FDG and (18)F-FET uptake in experimental soft tissue infection. Eur J Nucl Med Mol Imaging 29:648–654
Kracht LW, Miletic H, Busch S et al (2004) Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10:7163–7170
Salber D, Stoffels G, Oros-Peusquens AM et al (2010) Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas. J Nucl Med 51:790–797
Salber D, Stoffels G, Pauleit D et al (2006) Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. Nucl Med Biol 33:1029–1035
Stummer W, van den Bent MJ, Westphal M (2011) Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 153:1211–1218
Scott JN, Brasher PM, Sevick RJ et al (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949
Borgwardt L, Hojgaard L, Carstensen H et al (2005) Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 23:3030–3037
Padma MV, Jacobs M, Sequeira P et al (2004) Functional imaging in Lhermitte-Duclose disease. Mol Imaging Biol 6:319–323
Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294
Floeth FW, Pauleit D, Sabel M et al (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527
Popperl G, Kreth FW, Mehrkens JH et al (2007) FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 34:1933–1942
Calcagni ML, Galli G, Giordano A et al (2011) Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med 36:841–847
Pauleit D, Floeth F, Hamacher K et al (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687
Pirotte B, Goldman S, Massager N et al (2004) Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101:476–483
Mehrkens JH, Popperl G, Rachinger W et al (2008) The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 88:27–35
Popperl G, Gotz C, Rachinger W et al (2006) Serial O-(2-[18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 33:792–800
Popperl G, Gotz C, Rachinger W et al (2004) Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31:1464–1470
Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861–1867
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this paper
Cite this paper
Law, I. (2012). Nuclear Medicine Imaging of Brain Tumors. In: Hodler, J., von Schulthess, G.K., Zollikofer, C.L. (eds) Diseases of the Brain, Head & Neck, Spine 2012–2015. Springer, Milano. https://doi.org/10.1007/978-88-470-2628-5_32
Download citation
DOI: https://doi.org/10.1007/978-88-470-2628-5_32
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2627-8
Online ISBN: 978-88-470-2628-5
eBook Packages: MedicineMedicine (R0)